{"transactions":[{"id":734178,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":25460,"kind":"person","name":"Grissinger Michael","position":1,"cik":"0001757601","reported_name":"Grissinger Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-06-17T23:09:50.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":12555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":12555,"derivative":{"exercise_price":0.7293,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":12555},"source":{"system":"sec-edgar","filing":"0001104659-26-075286","document":"tm2618211-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1757601/000110465926075286/tm2618211-8_4seq1.xml","form_type":"4"}},{"id":734177,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":25460,"kind":"person","name":"Grissinger Michael","position":1,"cik":"0001757601","reported_name":"Grissinger Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T23:09:50.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":3135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":6024,"source":{"system":"sec-edgar","filing":"0001104659-26-075286","document":"tm2618211-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1757601/000110465926075286/tm2618211-8_4seq1.xml","form_type":"4"}},{"id":734329,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37306,"kind":"person","name":"Gruia Gabriela","position":1,"cik":"0001860326","reported_name":"Gruia Gabriela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-06-17T23:08:24.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":12555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":12555,"derivative":{"exercise_price":0.7293,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":12555},"source":{"system":"sec-edgar","filing":"0001104659-26-075284","document":"tm2618211-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860326/000110465926075284/tm2618211-7_4seq1.xml","form_type":"4"}},{"id":734328,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37306,"kind":"person","name":"Gruia Gabriela","position":1,"cik":"0001860326","reported_name":"Gruia Gabriela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T23:08:24.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":3135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4180,"source":{"system":"sec-edgar","filing":"0001104659-26-075284","document":"tm2618211-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860326/000110465926075284/tm2618211-7_4seq1.xml","form_type":"4"}},{"id":733274,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37112,"kind":"person","name":"Peters Richard","position":1,"cik":"0001697628","reported_name":"Peters Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-06-17T23:06:45.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":12555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":12555,"derivative":{"exercise_price":0.7293,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":12555},"source":{"system":"sec-edgar","filing":"0001104659-26-075283","document":"tm2618211-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1697628/000110465926075283/tm2618211-6_4seq1.xml","form_type":"4"}},{"id":733273,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37112,"kind":"person","name":"Peters Richard","position":1,"cik":"0001697628","reported_name":"Peters Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T23:06:45.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":3135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":6254,"source":{"system":"sec-edgar","filing":"0001104659-26-075283","document":"tm2618211-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1697628/000110465926075283/tm2618211-6_4seq1.xml","form_type":"4"}},{"id":733734,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":36126,"kind":"person","name":"HENNEMAN JOHN B III","position":1,"cik":"0001187572","reported_name":"HENNEMAN JOHN B III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-06-17T23:05:47.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":12555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":12555,"derivative":{"exercise_price":0.7293,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":12555},"source":{"system":"sec-edgar","filing":"0001104659-26-075282","document":"tm2618211-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1187572/000110465926075282/tm2618211-5_4seq1.xml","form_type":"4"}},{"id":733733,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":36126,"kind":"person","name":"HENNEMAN JOHN B III","position":1,"cik":"0001187572","reported_name":"HENNEMAN JOHN B III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T23:05:47.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":3135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":13364,"source":{"system":"sec-edgar","filing":"0001104659-26-075282","document":"tm2618211-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187572/000110465926075282/tm2618211-5_4seq1.xml","form_type":"4"}},{"id":733341,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37129,"kind":"person","name":"BIZZARI JEAN-PIERRE","position":1,"cik":"0001630914","reported_name":"BIZZARI JEAN-PIERRE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-06-17T23:04:37.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":12555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":12555,"derivative":{"exercise_price":0.7293,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":12555},"source":{"system":"sec-edgar","filing":"0001104659-26-075281","document":"tm2618211-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1630914/000110465926075281/tm2618211-4_4seq1.xml","form_type":"4"}},{"id":733340,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37129,"kind":"person","name":"BIZZARI JEAN-PIERRE","position":1,"cik":"0001630914","reported_name":"BIZZARI JEAN-PIERRE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T23:04:37.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":3135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4180,"source":{"system":"sec-edgar","filing":"0001104659-26-075281","document":"tm2618211-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630914/000110465926075281/tm2618211-4_4seq1.xml","form_type":"4"}},{"id":734438,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37324,"kind":"person","name":"Duey Marc","position":1,"cik":"0001925150","reported_name":"Duey Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-06-17T23:03:35.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":12555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":12555,"derivative":{"exercise_price":0.7293,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":12555},"source":{"system":"sec-edgar","filing":"0001104659-26-075280","document":"tm2618211-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1925150/000110465926075280/tm2618211-3_4seq1.xml","form_type":"4"}},{"id":734437,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37324,"kind":"person","name":"Duey Marc","position":1,"cik":"0001925150","reported_name":"Duey Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T23:03:35.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":3135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":259290,"source":{"system":"sec-edgar","filing":"0001104659-26-075280","document":"tm2618211-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1925150/000110465926075280/tm2618211-3_4seq1.xml","form_type":"4"}},{"id":734453,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37329,"kind":"person","name":"Pamukcu Rifat","position":1,"cik":"0001929298","reported_name":"Pamukcu Rifat","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-06-17T23:03:04.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":12555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":12555,"derivative":{"exercise_price":0.7293,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":12555},"source":{"system":"sec-edgar","filing":"0001104659-26-075279","document":"tm2618211-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1929298/000110465926075279/tm2618211-2_4seq1.xml","form_type":"4"}},{"id":734452,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37329,"kind":"person","name":"Pamukcu Rifat","position":1,"cik":"0001929298","reported_name":"Pamukcu Rifat","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T23:03:04.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":3135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":8581,"source":{"system":"sec-edgar","filing":"0001104659-26-075279","document":"tm2618211-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929298/000110465926075279/tm2618211-2_4seq1.xml","form_type":"4"}},{"id":733129,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-06-17T23:02:32.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":12555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":12555,"derivative":{"exercise_price":0.7293,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":12555},"source":{"system":"sec-edgar","filing":"0001104659-26-075278","document":"tm2618211-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926075278/tm2618211-1_4seq1.xml","form_type":"4"}},{"id":733128,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T23:02:32.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":3135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":48910,"source":{"system":"sec-edgar","filing":"0001104659-26-075278","document":"tm2618211-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926075278/tm2618211-1_4seq1.xml","form_type":"4"}},{"id":822484,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37112,"kind":"person","name":"Peters Richard","position":1,"cik":"0001697628","reported_name":"Peters Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrant","published_at":"2026-04-01T20:15:17.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":123915,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On March 30, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on March 31, 2026, (i) pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 123,915 shares of the Issuer's common stock (\"Shares\") at a purchase price of $0.808, less the $0.001 exercise price, per Pre-Funded Warrant and (ii) accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 123,915 Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 30, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on March 31, 2026, (i) pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 123,915 shares of the Issuer's common stock (\"Shares\") at a purchase price of $0.808, less the $0.001 exercise price, per Pre-Funded Warrant and (ii) accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 123,915 Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Warrants are immediately exercisable, subject to the Beneficial Ownership Limitation. The Common Warrants will expire on the earlier of (ii) December 31, 2029, and (ii) 30 calendars days after the date upon which the Pre-Funded Warrant is exercised, proportional to the amount of such exercise."}],"balance_after":123915,"derivative":{"exercise_price":0.683,"exercise_date":"2026-03-31","underlying":"Common Stock","underlying_shares":123915},"source":{"system":"sec-edgar","filing":"0001104659-26-038518","document":"tm2610878-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1697628/000110465926038518/tm2610878-1_4seq1.xml","form_type":"4"}},{"id":822483,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37112,"kind":"person","name":"Peters Richard","position":1,"cik":"0001697628","reported_name":"Peters Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2026-04-01T20:15:17.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":123915,"price":0.807,"value":99999.405,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On March 30, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on March 31, 2026, (i) pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 123,915 shares of the Issuer's common stock (\"Shares\") at a purchase price of $0.808, less the $0.001 exercise price, per Pre-Funded Warrant and (ii) accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 123,915 Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are immediately exercisable at any time after the date of issuance. Pursuant to the terms of the Pre-Funded Warrants, the Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise (the \"Beneficial Ownership Limitation\")"}],"balance_after":123915,"derivative":{"exercise_price":0.001,"exercise_date":"2026-03-31","underlying":"Common Stock","underlying_shares":123915},"source":{"system":"sec-edgar","filing":"0001104659-26-038518","document":"tm2610878-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1697628/000110465926038518/tm2610878-1_4seq1.xml","form_type":"4"}},{"id":822478,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Warrant","published_at":"2026-04-01T16:15:55.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":30978,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On March 30, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on March 31, 2026, (i) pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 30,978 shares of the Issuer's common stock (\"Shares\") at a purchase price of $0.808, less the $0.001 exercise price, per Pre-Funded Warrant and (ii) accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 30,978 Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 30, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on March 31, 2026, (i) pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 30,978 shares of the Issuer's common stock (\"Shares\") at a purchase price of $0.808, less the $0.001 exercise price, per Pre-Funded Warrant and (ii) accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 30,978 Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Warrants are immediately exercisable, subject to the Beneficial Ownership Limitation. The Common Warrants will expire on the earlier of (ii) December 31, 2029, and (ii) 30 calendars days after the date upon which the Pre-Funded Warrant is exercised, proportional to the amount of such exercise."}],"balance_after":30978,"derivative":{"exercise_price":0.683,"exercise_date":"2026-03-31","underlying":"Common Stock","underlying_shares":30978},"source":{"system":"sec-edgar","filing":"0001104659-26-038522","document":"tm2610878-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465926038522/tm2610878-2_4seq1.xml","form_type":"4"}},{"id":822477,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Pre-Funded Warrant","published_at":"2026-04-01T16:15:55.000Z","date":"2026-03-31","kind":"purchase","planned":false,"acquired":true,"shares":30978,"price":0.807,"value":24999.246,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On March 30, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on March 31, 2026, (i) pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 30,978 shares of the Issuer's common stock (\"Shares\") at a purchase price of $0.808, less the $0.001 exercise price, per Pre-Funded Warrant and (ii) accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 30,978 Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are immediately exercisable at any time after the date of issuance. Pursuant to the terms of the Pre-Funded Warrants, the Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise (the \"Beneficial Ownership Limitation\")"}],"balance_after":30978,"derivative":{"exercise_price":0.001,"exercise_date":"2026-03-31","underlying":"Common Stock","underlying_shares":30978},"source":{"system":"sec-edgar","filing":"0001104659-26-038522","document":"tm2610878-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465926038522/tm2610878-2_4seq1.xml","form_type":"4"}},{"id":841919,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-03-16T18:07:28.000Z","date":"2026-03-12","kind":"grant","planned":false,"acquired":true,"shares":80700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent of these options vest on March 12, 2027, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":80700,"derivative":{"exercise_price":0.765,"expiration_date":"2036-03-12","underlying":"Common Stock","underlying_shares":80700},"source":{"system":"sec-edgar","filing":"0001104659-26-028656","document":"tm268953-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465926028656/tm268953-2_4seq1.xml","form_type":"4"}},{"id":841918,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2026-03-16T18:07:28.000Z","date":"2026-03-12","kind":"grant","planned":false,"acquired":true,"shares":20175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 12, 2027, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":393895,"source":{"system":"sec-edgar","filing":"0001104659-26-028656","document":"tm268953-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465926028656/tm268953-2_4seq1.xml","form_type":"4"}},{"id":840973,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-03-16T18:06:04.000Z","date":"2026-03-12","kind":"grant","planned":false,"acquired":true,"shares":40380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of these options vest on March 12, 2027, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":40380,"derivative":{"exercise_price":0.765,"expiration_date":"2036-03-12","underlying":"Common Stock","underlying_shares":40380},"source":{"system":"sec-edgar","filing":"0001104659-26-028653","document":"tm268953-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465926028653/tm268953-1_4seq1.xml","form_type":"4"}},{"id":840972,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Stock","published_at":"2026-03-16T18:06:04.000Z","date":"2026-03-12","kind":"grant","planned":false,"acquired":true,"shares":10095,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 12, 2027, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":43528,"source":{"system":"sec-edgar","filing":"0001104659-26-028653","document":"tm268953-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465926028653/tm268953-1_4seq1.xml","form_type":"4"}},{"id":925499,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Warrant","published_at":"2026-02-02T16:08:08.000Z","date":"2026-01-30","kind":"purchase","planned":false,"acquired":true,"shares":28100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the second year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the second year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."}],"balance_after":28100,"derivative":{"exercise_price":0.765,"exercise_date":"2026-01-30","underlying":"Common Stock","underlying_shares":28100},"source":{"system":"sec-edgar","filing":"0001104659-26-009206","document":"tm264801-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465926009206/tm264801-2_4seq1.xml","form_type":"4"}},{"id":925498,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2026-02-02T16:08:08.000Z","date":"2026-01-30","kind":"purchase","planned":false,"acquired":true,"shares":28100,"price":0.89,"value":25009.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On January 28, 2026, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement, which closed on January 30, 2026, an aggregate of 28,100 shares of the Issuer's common stock (the \"Shares\") at a purchase price of $0.89 per Share. The Reporting Person also received accompanying common warrants (the \"Common Warrants\") to purchase up to an aggregate of 28,100 Shares."}],"balance_after":373720,"source":{"system":"sec-edgar","filing":"0001104659-26-009206","document":"tm264801-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465926009206/tm264801-2_4seq1.xml","form_type":"4"}},{"id":924457,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Warrant","published_at":"2026-02-02T16:05:34.000Z","date":"2026-01-30","kind":"purchase","planned":false,"acquired":true,"shares":5700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the second year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the second year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."}],"balance_after":5700,"derivative":{"exercise_price":0.765,"exercise_date":"2026-01-30","underlying":"Common Stock","underlying_shares":5700},"source":{"system":"sec-edgar","filing":"0001104659-26-009203","document":"tm264801-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465926009203/tm264801-1_4seq1.xml","form_type":"4"}},{"id":924456,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Stock","published_at":"2026-02-02T16:05:34.000Z","date":"2026-01-30","kind":"purchase","planned":false,"acquired":true,"shares":5700,"price":0.89,"value":5073.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 28, 2026, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement, which closed on January 30, 2026, an aggregate of 5,700 shares of the Issuer's common stock (the \"Shares\") at a purchase price of $0.89 per Share. The Reporting Person also received accompanying common warrants (the \"Common Warrants\") to purchase up to an aggregate of 5,700 Shares."}],"balance_after":33433,"source":{"system":"sec-edgar","filing":"0001104659-26-009203","document":"tm264801-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465926009203/tm264801-1_4seq1.xml","form_type":"4"}},{"id":972773,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37324,"kind":"person","name":"Duey Marc","position":1,"cik":"0001925150","reported_name":"Duey Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrant","published_at":"2025-12-11T13:31:55.000Z","date":"2025-12-10","kind":"purchase","planned":false,"acquired":true,"shares":21459,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the fifth year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the fifth year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."}],"balance_after":21459,"derivative":{"exercise_price":1.04,"exercise_date":"2025-12-10","underlying":"Common Stock","underlying_shares":21459},"source":{"system":"sec-edgar","filing":"0001104659-25-120156","document":"tm2533219-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1925150/000110465925120156/tm2533219-3_4seq1.xml","form_type":"4"}},{"id":972772,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37324,"kind":"person","name":"Duey Marc","position":1,"cik":"0001925150","reported_name":"Duey Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-11T13:31:55.000Z","date":"2025-12-10","kind":"purchase","planned":false,"acquired":true,"shares":21459,"price":1.165,"value":24999.735,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 8, 2025, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on December 10, 2025 an aggregate of 21,459 shares of the Issuer's common stock (\"Shares\") at a purchase price of $1.165. The Reporting Person also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 21,459 Shares."}],"balance_after":256155,"source":{"system":"sec-edgar","filing":"0001104659-25-120156","document":"tm2533219-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1925150/000110465925120156/tm2533219-3_4seq1.xml","form_type":"4"}},{"id":972369,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Warrant","published_at":"2025-12-11T08:31:02.000Z","date":"2025-12-10","kind":"purchase","planned":false,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the fifth year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the fifth year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."}],"balance_after":5000,"derivative":{"exercise_price":1.04,"exercise_date":"2025-12-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-25-120155","document":"tm2533219-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465925120155/tm2533219-2_4seq1.xml","form_type":"4"}},{"id":972368,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Stock","published_at":"2025-12-11T08:31:02.000Z","date":"2025-12-10","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":1.165,"value":5825.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 8, 2025, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on December 10, 2025 an aggregate of 5,000 shares of the Issuer's common stock (\"Shares\") at a purchase price of $1.165. The Reporting Person also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 5,000 Shares."}],"balance_after":27733,"source":{"system":"sec-edgar","filing":"0001104659-25-120155","document":"tm2533219-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465925120155/tm2533219-2_4seq1.xml","form_type":"4"}},{"id":972789,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Warrants","published_at":"2025-12-11T08:30:14.000Z","date":"2025-12-10","kind":"purchase","planned":false,"acquired":true,"shares":21459,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"On December 8, 2025, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on December 10, 2025 pre-funded warrants (\"Pre-Funded Warrants\") to purchase an aggregate of 21,459 shares of the Issuer's common stock (\"Shares\") at a purchase price of $1.165 per Pre-Funded Warrant. The Reporting Person also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 21,459 Shares."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Common Warrants are immediately exercisable, subject to the Beneficial Ownership Limitation. The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the fifth year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Common Warrants are immediately exercisable, subject to the Beneficial Ownership Limitation. The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the fifth year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."}],"balance_after":21459,"derivative":{"exercise_price":1.04,"exercise_date":"2025-12-10","underlying":"Common Stock","underlying_shares":21459},"source":{"system":"sec-edgar","filing":"0001104659-25-120152","document":"tm2533219-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465925120152/tm2533219-1_4seq1.xml","form_type":"4"}},{"id":972788,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Pre-Funded Warrant","published_at":"2025-12-11T08:30:14.000Z","date":"2025-12-10","kind":"purchase","planned":false,"acquired":true,"shares":21459,"price":1.165,"value":24999.735,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"On December 8, 2025, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on December 10, 2025 pre-funded warrants (\"Pre-Funded Warrants\") to purchase an aggregate of 21,459 shares of the Issuer's common stock (\"Shares\") at a purchase price of $1.165 per Pre-Funded Warrant. The Reporting Person also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 21,459 Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are immediately exercisable at any time after the date of issuance. Pursuant to the terms of the Pre-Funded Warrants, the Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise (the \"Beneficial Ownership Limitation\")"}],"balance_after":21459,"derivative":{"exercise_price":0.0001,"exercise_date":"2025-12-10","underlying":"Common Stock","underlying_shares":21459},"source":{"system":"sec-edgar","filing":"0001104659-25-120152","document":"tm2533219-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465925120152/tm2533219-1_4seq1.xml","form_type":"4"}},{"id":1117241,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-06-09T20:07:40.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":4185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4185,"derivative":{"exercise_price":1.81,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":4185},"source":{"system":"sec-edgar","filing":"0001104659-25-057823","document":"tm2517366-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465925057823/tm2517366-8_4seq1.xml","form_type":"4"}},{"id":1117240,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:07:40.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":1045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 5, 2025, and which will vest and be settled in common stock on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":45775,"source":{"system":"sec-edgar","filing":"0001104659-25-057823","document":"tm2517366-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465925057823/tm2517366-8_4seq1.xml","form_type":"4"}},{"id":1117339,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37112,"kind":"person","name":"Peters Richard","position":1,"cik":"0001697628","reported_name":"Peters Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-06-09T20:06:53.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":4185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4185,"derivative":{"exercise_price":1.81,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":4185},"source":{"system":"sec-edgar","filing":"0001104659-25-057821","document":"tm2517366-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1697628/000110465925057821/tm2517366-7_4seq1.xml","form_type":"4"}},{"id":1117338,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37112,"kind":"person","name":"Peters Richard","position":1,"cik":"0001697628","reported_name":"Peters Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:06:53.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":1045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 5, 2025, and which will vest and be settled in common stock on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":3119,"source":{"system":"sec-edgar","filing":"0001104659-25-057821","document":"tm2517366-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1697628/000110465925057821/tm2517366-7_4seq1.xml","form_type":"4"}},{"id":1118257,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37329,"kind":"person","name":"Pamukcu Rifat","position":1,"cik":"0001929298","reported_name":"Pamukcu Rifat","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-06-09T20:06:08.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":4185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in full on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4185,"derivative":{"exercise_price":1.81,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":4185},"source":{"system":"sec-edgar","filing":"0001104659-25-057818","document":"tm2517366-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1929298/000110465925057818/tm2517366-6_4seq1.xml","form_type":"4"}},{"id":1118256,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37329,"kind":"person","name":"Pamukcu Rifat","position":1,"cik":"0001929298","reported_name":"Pamukcu Rifat","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:06:08.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":1045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 5, 2025, and which will vest and be settled in common stock on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":5446,"source":{"system":"sec-edgar","filing":"0001104659-25-057818","document":"tm2517366-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929298/000110465925057818/tm2517366-6_4seq1.xml","form_type":"4"}},{"id":1117611,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":36126,"kind":"person","name":"HENNEMAN JOHN B III","position":1,"cik":"0001187572","reported_name":"HENNEMAN JOHN B III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-06-09T20:05:29.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":4185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4185,"derivative":{"exercise_price":1.81,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":4185},"source":{"system":"sec-edgar","filing":"0001104659-25-057815","document":"tm2517366-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1187572/000110465925057815/tm2517366-5_4seq1.xml","form_type":"4"}},{"id":1117610,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":36126,"kind":"person","name":"HENNEMAN JOHN B III","position":1,"cik":"0001187572","reported_name":"HENNEMAN JOHN B III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:05:29.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":1045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 5, 2025, and which will vest and be settled in common stock on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":10229,"source":{"system":"sec-edgar","filing":"0001104659-25-057815","document":"tm2517366-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187572/000110465925057815/tm2517366-5_4seq1.xml","form_type":"4"}},{"id":1118107,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37306,"kind":"person","name":"Gruia Gabriela","position":1,"cik":"0001860326","reported_name":"Gruia Gabriela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-06-09T20:04:28.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":4185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4185,"derivative":{"exercise_price":1.81,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":4185},"source":{"system":"sec-edgar","filing":"0001104659-25-057813","document":"tm2517366-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1860326/000110465925057813/tm2517366-4_4seq1.xml","form_type":"4"}},{"id":1118106,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37306,"kind":"person","name":"Gruia Gabriela","position":1,"cik":"0001860326","reported_name":"Gruia Gabriela","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:04:28.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":1045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 5, 2025, and which will vest and be settled in common stock on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":1045,"source":{"system":"sec-edgar","filing":"0001104659-25-057813","document":"tm2517366-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1860326/000110465925057813/tm2517366-4_4seq1.xml","form_type":"4"}},{"id":1118003,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":25460,"kind":"person","name":"Grissinger Michael","position":1,"cik":"0001757601","reported_name":"Grissinger Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-06-09T20:03:35.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":4185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4185,"derivative":{"exercise_price":1.81,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":4185},"source":{"system":"sec-edgar","filing":"0001104659-25-057811","document":"tm2517366-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1757601/000110465925057811/tm2517366-3_4seq1.xml","form_type":"4"}},{"id":1118002,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":25460,"kind":"person","name":"Grissinger Michael","position":1,"cik":"0001757601","reported_name":"Grissinger Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:03:35.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":1045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 5, 2025, and which will vest and be settled in common stock on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":2889,"source":{"system":"sec-edgar","filing":"0001104659-25-057811","document":"tm2517366-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1757601/000110465925057811/tm2517366-3_4seq1.xml","form_type":"4"}},{"id":1118253,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37324,"kind":"person","name":"Duey Marc","position":1,"cik":"0001925150","reported_name":"Duey Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-06-09T20:02:54.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":4185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in full on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4185,"derivative":{"exercise_price":1.81,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":4185},"source":{"system":"sec-edgar","filing":"0001104659-25-057809","document":"tm2517366-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1925150/000110465925057809/tm2517366-2_4seq1.xml","form_type":"4"}},{"id":1118252,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37324,"kind":"person","name":"Duey Marc","position":1,"cik":"0001925150","reported_name":"Duey Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:02:54.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":1045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 5, 2025, and which will vest and be settled in common stock on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":234696,"source":{"system":"sec-edgar","filing":"0001104659-25-057809","document":"tm2517366-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1925150/000110465925057809/tm2517366-2_4seq1.xml","form_type":"4"}},{"id":1117358,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37129,"kind":"person","name":"BIZZARI JEAN-PIERRE","position":1,"cik":"0001630914","reported_name":"BIZZARI JEAN-PIERRE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-06-09T20:01:14.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":4185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4185,"derivative":{"exercise_price":1.81,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":4185},"source":{"system":"sec-edgar","filing":"0001104659-25-057806","document":"tm2517366-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1630914/000110465925057806/tm2517366-1_4seq1.xml","form_type":"4"}},{"id":1117357,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37129,"kind":"person","name":"BIZZARI JEAN-PIERRE","position":1,"cik":"0001630914","reported_name":"BIZZARI JEAN-PIERRE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:01:14.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":1045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 5, 2025, and which will vest and be settled in common stock on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":1045,"source":{"system":"sec-edgar","filing":"0001104659-25-057806","document":"tm2517366-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630914/000110465925057806/tm2517366-1_4seq1.xml","form_type":"4"}},{"id":1177782,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2025-04-04T07:30:11.000Z","date":"2025-04-03","kind":"purchase","planned":false,"acquired":true,"shares":2497,"price":1.8,"value":4494.6,"ownership":{"direct":true},"balance_after":345620,"source":{"system":"sec-edgar","filing":"0001104659-25-031991","document":"tm2511518-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465925031991/tm2511518-1_4seq1.xml","form_type":"4"}},{"id":1177781,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2025-04-04T07:30:11.000Z","date":"2025-04-03","kind":"purchase","planned":false,"acquired":true,"shares":3003,"price":1.87,"value":5615.61,"ownership":{"direct":true},"balance_after":343123,"source":{"system":"sec-edgar","filing":"0001104659-25-031991","document":"tm2511518-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465925031991/tm2511518-1_4seq1.xml","form_type":"4"}},{"id":1187672,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Stock Options (Right to Buy)","published_at":"2025-03-31T16:31:29.000Z","date":"2025-03-27","kind":"grant","planned":false,"acquired":true,"shares":13460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of these options vest on March 27, 2026, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":13460,"derivative":{"exercise_price":2.2,"expiration_date":"2035-03-28","underlying":"Common Stock","underlying_shares":13460},"source":{"system":"sec-edgar","filing":"0001104659-25-029920","document":"tm2510809-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465925029920/tm2510809-2_4seq1.xml","form_type":"4"}},{"id":1187671,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Stock","published_at":"2025-03-31T16:31:29.000Z","date":"2025-03-27","kind":"grant","planned":false,"acquired":true,"shares":3365,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 27, 2026, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":22733,"source":{"system":"sec-edgar","filing":"0001104659-25-029920","document":"tm2510809-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465925029920/tm2510809-2_4seq1.xml","form_type":"4"}},{"id":1188063,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2025-03-31T16:30:32.000Z","date":"2025-03-27","kind":"grant","planned":false,"acquired":true,"shares":26900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent of these options vest on March 27, 2026, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":26900,"derivative":{"exercise_price":2.2,"expiration_date":"2035-03-28","underlying":"Common Stock","underlying_shares":26900},"source":{"system":"sec-edgar","filing":"0001104659-25-029914","document":"tm2510809-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465925029914/tm2510809-1_4seq1.xml","form_type":"4"}},{"id":1188062,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2025-03-31T16:30:32.000Z","date":"2025-03-27","kind":"grant","planned":false,"acquired":true,"shares":6725,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 27, 2026, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":340120,"source":{"system":"sec-edgar","filing":"0001104659-25-029914","document":"tm2510809-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465925029914/tm2510809-1_4seq1.xml","form_type":"4"}},{"id":1381449,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37324,"kind":"person","name":"Duey Marc","position":1,"cik":"0001925150","reported_name":"Duey Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-25T21:42:04.000Z","date":"2024-10-18","kind":"sale","planned":false,"acquired":false,"shares":6462,"price":4.578,"value":29583.036,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person's sale of Issuer's common stock reported herein was automatically transacted by the Reporting Person's broker as a result of an insufficient cash position in the Reporting Person's brokerage account. Further, the Reporting Person's sale of Issuer's common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 (i) to the extent of 190 shares, with the Reporting Person's purchase of 190 shares of the Issuer's common stock at a price of $2.5837 on October 14, 2024, and (ii) to the extent of 6,272 shares, with the Reporting Person's purchase of 30,000 shares of the Issuer's common stock at a price of $4.39 per share on October 16, 2024. The Reporting Person has agreed to pay to Issuer $1,558.05 which represents the full amount of the profit realized in connection with the short-swing transaction."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were sold in multiple transactions on October 18, 2024, each at $4.578 per share."}],"balance_after":233651,"source":{"system":"sec-edgar","filing":"0001104659-24-111548","document":"tm2426908-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1925150/000110465924111548/tm2426908-1_4seq1.xml","form_type":"4"}},{"id":1382025,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2024-10-24T08:30:13.000Z","date":"2024-10-23","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":3.915,"value":1957.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.91 to $3.92, inclusive. The reporting person undertakes to provide to the issuer or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":333395,"source":{"system":"sec-edgar","filing":"0001104659-24-111031","document":"tm2426748-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924111031/tm2426748-1_4seq1.xml","form_type":"4"}},{"id":1384959,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37324,"kind":"person","name":"Duey Marc","position":1,"cik":"0001925150","reported_name":"Duey Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T12:30:55.000Z","date":"2024-10-16","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":4.39,"value":131700.0,"ownership":{"direct":true},"balance_after":240113,"source":{"system":"sec-edgar","filing":"0001104659-24-109386","document":"tm2426287-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1925150/000110465924109386/tm2426287-1_4seq1.xml","form_type":"4"}},{"id":1385975,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37324,"kind":"person","name":"Duey Marc","position":1,"cik":"0001925150","reported_name":"Duey Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-16T12:30:47.000Z","date":"2024-10-14","kind":"purchase","planned":false,"acquired":true,"shares":190,"price":2.58,"value":490.2,"ownership":{"direct":true},"balance_after":210113,"source":{"system":"sec-edgar","filing":"0001104659-24-108963","document":"tm2426059-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1925150/000110465924108963/tm2426059-5_4seq1.xml","form_type":"4"}},{"id":1385976,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2024-10-16T08:31:25.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":250,"price":2.9,"value":725.0,"ownership":{"direct":true},"balance_after":332895,"source":{"system":"sec-edgar","filing":"0001104659-24-108964","document":"tm2426059-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924108964/tm2426059-6_4seq1.xml","form_type":"4"}},{"id":1385657,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Stock","published_at":"2024-10-16T08:30:13.000Z","date":"2024-10-11","kind":"purchase","planned":false,"acquired":true,"shares":50,"price":2.4638,"value":123.19,"ownership":{"direct":true},"balance_after":19368,"source":{"system":"sec-edgar","filing":"0001104659-24-108962","document":"tm2426059-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465924108962/tm2426059-2_4seq1.xml","form_type":"4"}},{"id":1386432,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T12:31:44.000Z","date":"2024-10-11","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.68,"value":26800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.52 to $2.70, inclusive. The reporting person undertakes to provide to the issuer or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":44730,"source":{"system":"sec-edgar","filing":"0001104659-24-108377","document":"tm2426059-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465924108377/tm2426059-4_4seq1.xml","form_type":"4"}},{"id":1386782,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2024-10-15T08:31:01.000Z","date":"2024-10-14","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":2.59,"value":2590.0,"ownership":{"direct":true},"balance_after":332645,"source":{"system":"sec-edgar","filing":"0001104659-24-108375","document":"tm2426059-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924108375/tm2426059-3_4seq1.xml","form_type":"4"}},{"id":1386781,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2024-10-15T08:31:01.000Z","date":"2024-10-10","kind":"purchase","planned":false,"acquired":true,"shares":150,"price":2.54,"value":381.0,"ownership":{"direct":true},"balance_after":331645,"source":{"system":"sec-edgar","filing":"0001104659-24-108375","document":"tm2426059-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924108375/tm2426059-3_4seq1.xml","form_type":"4"}},{"id":1386449,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Stock","published_at":"2024-10-15T08:30:16.000Z","date":"2024-10-10","kind":"purchase","planned":false,"acquired":true,"shares":450,"price":2.61,"value":1174.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.55 to $2.618, inclusive. The reporting person undertakes to provide to the issuer or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":19318,"source":{"system":"sec-edgar","filing":"0001104659-24-108373","document":"tm2426059-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465924108373/tm2426059-1_4seq1.xml","form_type":"4"}},{"id":1471622,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-06-21T20:20:11.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":4185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4185,"derivative":{"exercise_price":4.07,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":4185},"source":{"system":"sec-edgar","filing":"0001104659-24-073950","document":"tm2417666-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465924073950/tm2417666-6_4seq1.xml","form_type":"4"}},{"id":1471621,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T20:20:11.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":1045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":34730,"source":{"system":"sec-edgar","filing":"0001104659-24-073950","document":"tm2417666-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465924073950/tm2417666-6_4seq1.xml","form_type":"4"}},{"id":1472274,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37329,"kind":"person","name":"Pamukcu Rifat","position":1,"cik":"0001929298","reported_name":"Pamukcu Rifat","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-06-21T20:19:20.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":4185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4185,"derivative":{"exercise_price":4.07,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":4185},"source":{"system":"sec-edgar","filing":"0001104659-24-073947","document":"tm2417666-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1929298/000110465924073947/tm2417666-5_4seq1.xml","form_type":"4"}},{"id":1472273,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37329,"kind":"person","name":"Pamukcu Rifat","position":1,"cik":"0001929298","reported_name":"Pamukcu Rifat","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T20:19:20.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":1045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4401,"source":{"system":"sec-edgar","filing":"0001104659-24-073947","document":"tm2417666-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929298/000110465924073947/tm2417666-5_4seq1.xml","form_type":"4"}},{"id":1471664,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37112,"kind":"person","name":"Peters Richard","position":1,"cik":"0001697628","reported_name":"Peters Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-06-21T20:18:13.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":4185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4185,"derivative":{"exercise_price":4.07,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":4185},"source":{"system":"sec-edgar","filing":"0001104659-24-073943","document":"tm2417666-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1697628/000110465924073943/tm2417666-4_4seq1.xml","form_type":"4"}},{"id":1471663,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37112,"kind":"person","name":"Peters Richard","position":1,"cik":"0001697628","reported_name":"Peters Richard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T20:18:13.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":1045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":2074,"source":{"system":"sec-edgar","filing":"0001104659-24-073943","document":"tm2417666-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1697628/000110465924073943/tm2417666-4_4seq1.xml","form_type":"4"}},{"id":1471868,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":36126,"kind":"person","name":"HENNEMAN JOHN B III","position":1,"cik":"0001187572","reported_name":"HENNEMAN JOHN B III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-06-21T20:17:29.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":4185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4185,"derivative":{"exercise_price":4.07,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":4185},"source":{"system":"sec-edgar","filing":"0001104659-24-073941","document":"tm2417666-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1187572/000110465924073941/tm2417666-3_4seq1.xml","form_type":"4"}},{"id":1471867,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":36126,"kind":"person","name":"HENNEMAN JOHN B III","position":1,"cik":"0001187572","reported_name":"HENNEMAN JOHN B III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T20:17:29.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":1045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":9184,"source":{"system":"sec-edgar","filing":"0001104659-24-073941","document":"tm2417666-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187572/000110465924073941/tm2417666-3_4seq1.xml","form_type":"4"}},{"id":1472125,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":25460,"kind":"person","name":"Grissinger Michael","position":1,"cik":"0001757601","reported_name":"Grissinger Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-06-21T20:16:34.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":4185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4185,"derivative":{"exercise_price":4.07,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":4185},"source":{"system":"sec-edgar","filing":"0001104659-24-073936","document":"tm2417666-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1757601/000110465924073936/tm2417666-2_4seq1.xml","form_type":"4"}},{"id":1472124,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":25460,"kind":"person","name":"Grissinger Michael","position":1,"cik":"0001757601","reported_name":"Grissinger Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T20:16:34.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":1045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":1844,"source":{"system":"sec-edgar","filing":"0001104659-24-073936","document":"tm2417666-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1757601/000110465924073936/tm2417666-2_4seq1.xml","form_type":"4"}},{"id":1472271,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37324,"kind":"person","name":"Duey Marc","position":1,"cik":"0001925150","reported_name":"Duey Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-06-21T20:15:11.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":4185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4185,"derivative":{"exercise_price":4.07,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":4185},"source":{"system":"sec-edgar","filing":"0001104659-24-073932","document":"tm2417666-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1925150/000110465924073932/tm2417666-1_4seq1.xml","form_type":"4"}},{"id":1472270,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37324,"kind":"person","name":"Duey Marc","position":1,"cik":"0001925150","reported_name":"Duey Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T20:15:11.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":1045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":209923,"source":{"system":"sec-edgar","filing":"0001104659-24-073932","document":"tm2417666-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1925150/000110465924073932/tm2417666-1_4seq1.xml","form_type":"4"}},{"id":1530721,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":91588,"kind":"person","name":"Mirza Nadeem Q.","position":1,"cik":"0002021015","reported_name":"Mirza Nadeem Q.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to Purchase)","published_at":"2024-05-02T16:16:29.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":26920,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4). Twenty-five percent of these options vest on May 1, 2025, with the remaining options vesting ratably over the following 36 months, subject to the Reporting Person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":26920,"derivative":{"exercise_price":5.25,"expiration_date":"2034-05-01","underlying":"Common Stock","underlying_shares":29920},"source":{"system":"sec-edgar","filing":"0001104659-24-056402","document":"tm2413094-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2021015/000110465924056402/tm2413094-2_4seq1.xml","form_type":"4"}},{"id":1530720,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":91588,"kind":"person","name":"Mirza Nadeem Q.","position":1,"cik":"0002021015","reported_name":"Mirza Nadeem Q.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-05-02T16:16:29.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":6730,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4). These shares represent restricted stock units (\"RSUs\") and shall vest and be settled in the Issuer's common stock, on a one-for-one basis in three (3) equal annual installments beginning on May 1, 2025, until vested in full, subject to the Reporting Person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":6730,"source":{"system":"sec-edgar","filing":"0001104659-24-056402","document":"tm2413094-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2021015/000110465924056402/tm2413094-2_4seq1.xml","form_type":"4"}},{"id":1558186,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-28T17:59:46.000Z","date":"2024-03-28","kind":"grant","planned":false,"acquired":true,"shares":13460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of these options vest on March 28, 2025, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":13460,"derivative":{"exercise_price":6.69,"expiration_date":"2024-03-28","underlying":"Common Stock","underlying_shares":13460},"source":{"system":"sec-edgar","filing":"0001104659-24-040645","document":"tm2410009-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465924040645/tm2410009-2_4seq1.xml","form_type":"4"}},{"id":1558185,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Stock","published_at":"2024-03-28T17:59:46.000Z","date":"2024-03-28","kind":"grant","planned":false,"acquired":true,"shares":3365,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and shall vest and be settled in the Issuer's common stock (\"Common Stock\") in three (3) equal annual installments beginning on March 28, 2025, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":18868,"source":{"system":"sec-edgar","filing":"0001104659-24-040645","document":"tm2410009-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465924040645/tm2410009-2_4seq1.xml","form_type":"4"}},{"id":1558623,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-28T17:57:27.000Z","date":"2024-03-28","kind":"grant","planned":false,"acquired":true,"shares":26900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent of these options vest on March 28, 2025, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":26900,"derivative":{"exercise_price":6.69,"expiration_date":"2024-03-28","underlying":"Common Stock","underlying_shares":26900},"source":{"system":"sec-edgar","filing":"0001104659-24-040642","document":"tm2410009-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924040642/tm2410009-1_4seq1.xml","form_type":"4"}},{"id":1558622,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2024-03-28T17:57:27.000Z","date":"2024-03-28","kind":"grant","planned":false,"acquired":true,"shares":6725,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and shall vest and be settled in the Issuer's common stock (\"Common Stock\") in three (3) equal annual installments beginning on March 28, 2025, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":331495,"source":{"system":"sec-edgar","filing":"0001104659-24-040642","document":"tm2410009-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924040642/tm2410009-1_4seq1.xml","form_type":"4"}},{"id":1576123,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tranche B Warrant","published_at":"2024-03-15T00:53:36.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":3430,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price of the Tranche B Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred."}],"balance_after":3430,"derivative":{"exercise_date":"2024-03-13","underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0001104659-24-034672","document":"tm248935-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465924034672/tm248935-3_4seq1.xml","form_type":"4"}},{"id":1576122,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tranche A Warrant","published_at":"2024-03-15T00:53:36.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":3430,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the Tranche A Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred."}],"balance_after":3430,"derivative":{"exercise_date":"2024-03-13","underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0001104659-24-034672","document":"tm248935-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465924034672/tm248935-3_4seq1.xml","form_type":"4"}},{"id":1576121,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-15T00:53:36.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":6860,"price":7.29,"value":50009.4,"ownership":{"direct":true},"balance_after":33685,"source":{"system":"sec-edgar","filing":"0001104659-24-034672","document":"tm248935-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465924034672/tm248935-3_4seq1.xml","form_type":"4"}},{"id":1576416,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":36126,"kind":"person","name":"HENNEMAN JOHN B III","position":1,"cik":"0001187572","reported_name":"HENNEMAN JOHN B III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tranche B Warrant","published_at":"2024-03-15T00:52:35.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":3430,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price of the Tranche B Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred."}],"balance_after":3430,"derivative":{"exercise_date":"2024-03-13","underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0001104659-24-034671","document":"tm248935-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1187572/000110465924034671/tm248935-2_4seq1.xml","form_type":"4"}},{"id":1576415,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":36126,"kind":"person","name":"HENNEMAN JOHN B III","position":1,"cik":"0001187572","reported_name":"HENNEMAN JOHN B III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tranche A Warrant","published_at":"2024-03-15T00:52:35.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":3430,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the Tranche A Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred."}],"balance_after":3430,"derivative":{"exercise_date":"2024-03-13","underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0001104659-24-034671","document":"tm248935-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1187572/000110465924034671/tm248935-2_4seq1.xml","form_type":"4"}},{"id":1576414,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":36126,"kind":"person","name":"HENNEMAN JOHN B III","position":1,"cik":"0001187572","reported_name":"HENNEMAN JOHN B III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-15T00:52:35.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":6860,"price":7.29,"value":50009.4,"ownership":{"direct":true},"balance_after":8139,"source":{"system":"sec-edgar","filing":"0001104659-24-034671","document":"tm248935-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187572/000110465924034671/tm248935-2_4seq1.xml","form_type":"4"}},{"id":1576169,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Tranche B Warrant","published_at":"2024-03-14T20:54:37.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":505,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price of the Tranche B Warrants is as follows: 505 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred."}],"balance_after":505,"derivative":{"exercise_date":"2024-03-13","underlying":"Common Stock","underlying_shares":505},"source":{"system":"sec-edgar","filing":"0001104659-24-034673","document":"tm248935-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465924034673/tm248935-4_4seq1.xml","form_type":"4"}},{"id":1576168,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Tranche A Warrant","published_at":"2024-03-14T20:54:37.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":505,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the Tranche A Warrants is as follows: 505 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred."}],"balance_after":505,"derivative":{"exercise_date":"2024-03-13","underlying":"Common Stock","underlying_shares":505},"source":{"system":"sec-edgar","filing":"0001104659-24-034673","document":"tm248935-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465924034673/tm248935-4_4seq1.xml","form_type":"4"}},{"id":1576167,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":54595,"kind":"person","name":"Hamill John P.","position":1,"cik":"0001716213","reported_name":"Hamill John P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SrVP/CFO/Prin Fin & Acct Ofcr"}}],"security":"Common Stock","published_at":"2024-03-14T20:54:37.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":1010,"price":7.29,"value":7362.9,"ownership":{"direct":true},"balance_after":15503,"source":{"system":"sec-edgar","filing":"0001104659-24-034673","document":"tm248935-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716213/000110465924034673/tm248935-4_4seq1.xml","form_type":"4"}},{"id":1576976,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Tranche B Warrant","published_at":"2024-03-14T20:51:23.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price of the Tranche B Warrants is as follows:  1,000 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred."}],"balance_after":1000,"derivative":{"exercise_date":"2024-03-13","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001104659-24-034670","document":"tm248935-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924034670/tm248935-1_4seq1.xml","form_type":"4"}},{"id":1576975,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Tranche A Warrant","published_at":"2024-03-14T20:51:23.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the Tranche A Warrants is as follows:  1,000 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred."}],"balance_after":1000,"derivative":{"exercise_date":"2024-03-13","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001104659-24-034670","document":"tm248935-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924034670/tm248935-1_4seq1.xml","form_type":"4"}},{"id":1576974,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2024-03-14T20:51:23.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":7.29,"value":14580.0,"ownership":{"direct":true},"balance_after":324770,"source":{"system":"sec-edgar","filing":"0001104659-24-034670","document":"tm248935-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924034670/tm248935-1_4seq1.xml","form_type":"4"}},{"id":1797920,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37329,"kind":"person","name":"Pamukcu Rifat","position":1,"cik":"0001929298","reported_name":"Pamukcu Rifat","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-08-25T01:52:29.000Z","date":"2023-08-23","kind":"grant","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests in full on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":2000,"derivative":{"exercise_price":3.65,"expiration_date":"2033-08-23","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001104659-23-095021","document":"tm2324788-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1929298/000110465923095021/tm2324788-8_4seq1.xml","form_type":"4"}},{"id":1797919,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37329,"kind":"person","name":"Pamukcu Rifat","position":1,"cik":"0001929298","reported_name":"Pamukcu Rifat","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2023-08-25T01:52:29.000Z","date":"2022-08-23","kind":"exercise","planned":false,"acquired":false,"shares":27187,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ZNZ Holdings LLC"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Following stockholder approval at the Issuer's annual stockholder's meeting, each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock (\"Common Stock\") at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Non-Voting Convertible Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Following stockholder approval at the Issuer's annual stockholder's meeting, each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock (\"Common Stock\") at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Non-Voting Convertible Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person serves as Manager Partner of ZNZ Holdings L.L.C."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":271870},"source":{"system":"sec-edgar","filing":"0001104659-23-095021","document":"tm2324788-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1929298/000110465923095021/tm2324788-8_4seq1.xml","form_type":"4"}},{"id":1797918,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37329,"kind":"person","name":"Pamukcu Rifat","position":1,"cik":"0001929298","reported_name":"Pamukcu Rifat","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2023-08-25T01:52:29.000Z","date":"2022-08-23","kind":"exercise","planned":false,"acquired":false,"shares":4928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Following stockholder approval at the Issuer's annual stockholder's meeting, each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock (\"Common Stock\") at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Non-Voting Convertible Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Following stockholder approval at the Issuer's annual stockholder's meeting, each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock (\"Common Stock\") at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Non-Voting Convertible Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":49280},"source":{"system":"sec-edgar","filing":"0001104659-23-095021","document":"tm2324788-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1929298/000110465923095021/tm2324788-8_4seq1.xml","form_type":"4"}},{"id":1797917,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":37329,"kind":"person","name":"Pamukcu Rifat","position":1,"cik":"0001929298","reported_name":"Pamukcu Rifat","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-25T01:52:29.000Z","date":"2022-08-23","kind":"exercise","planned":false,"acquired":true,"shares":271870,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By ZNZ Holdings LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Following stockholder approval at the Issuer's annual stockholder's meeting, each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock (\"Common Stock\") at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Non-Voting Convertible Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a one-for-20 reverse split, effective as of 5:00 p.m. Eastern Time on February 10, 2023"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person serves as Manager Partner of ZNZ Holdings L.L.C."}],"balance_after":14108,"source":{"system":"sec-edgar","filing":"0001104659-23-095021","document":"tm2324788-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1929298/000110465923095021/tm2324788-8_4seq1.xml","form_type":"4"}}],"next_cursor":"2023-08-25T01:52:29.000000Z,1797917"}